Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study

Overview

Journal Integr Med Rep

Date 2022 Sep 15

PMID 36105269

Authors

Joji Suzuki

Bianca Martin

Sara Prostko

Peter R Chai

Roger D Weiss

Affiliations

Soon will be listed here.

Abstract

Background: Opioid use disorder (OUD) remains a major public health concern. Despite the use of medications for OUD such as buprenorphine, the current gold-standard treatment, relapse in the context of increased craving remains common. Cannabidiol (CBD) has been shown to reduce cue-induced craving in individuals with OUD, but among those who were not receiving any buprenorphine treatment. This small proof-of-concept open-label study sought to evaluate the effect of CBD on cue-induced craving among individuals with OUD who were being actively treated with buprenorphine.

Methods: Participants ( = 5) received CBD (Epidiolex) 600 mg once daily for 3 consecutive days in an open-label manner. Primary outcome was cue-induced craving measured on a visual analog scale of 0 to 10, calculated as the difference in craving in response to drug-related versus neutral cues. The cue-reactivity paradigm was performed at baseline before CBD administration, and was repeated after 3 days of CBD. Secondary outcomes included scores on depression, anxiety, pain, opioid withdrawal, and side effects.

Results: All participants were actively taking buprenorphine for an average of 37.8 months (range 1-120 months). Cue-induced craving was significantly lower after CBD dosing compared with baseline (0.4 vs. 3.2, paired -test, = 0.0046). No significant changes in scores for depression, anxiety, pain, or opioid withdrawal were noted. CBD was well tolerated, although one participant experienced moderate sedation; otherwise, no other adverse effects were reported.

Conclusions: Given the high risk for bias in a small uncontrolled open label study such as this, results must be interpreted with caution. A larger adequately powered trial with a suitable control group is needed to confirm the finding that CBD may help to reduce cue-induced craving among individuals with OUD currently on buprenorphine treatment. Research should further evaluate whether adjunctive use of CBD can improve clinical outcomes for individuals with OUD maintained on buprenorphine. ClinicalTrials.gov (NCT04192370).

Citing Articles

Use and perceptions of Cannabidiol among individuals in treatment for opioid use disorder.

Kudrich C, Chen R, Meng Y, Bachi K, Hurd Y Harm Reduct J. 2024; 21(1):135.

PMID: 39020418 PMC: 11253449. DOI: 10.1186/s12954-024-01051-5.

The Therapeutic Potential of Cannabidiol in Revolutionising Opioid Use Disorder Management.

Le K, Au J, Hua J, Le K Cureus. 2024; 15(12):e50634.

PMID: 38226097 PMC: 10789504. DOI: 10.7759/cureus.50634.

Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review.

Lo L, MacCallum C, Nanson K, Koehn M, Mitchell I, Milloy M Can J Psychiatry. 2023; 68(8):557-571.

PMID: 37376827 PMC: 10411365. DOI: 10.1177/07067437231183525.

Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial.

Suzuki J, Prostko S, Szpak V, Chai P, Spagnolo P, Tenenbaum R Front Psychiatry. 2023; 14:1155984.

PMID: 37065899 PMC: 10098189. DOI: 10.3389/fpsyt.2023.1155984.

Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review.

Madeo G, Kapoor A, Giorgetti R, Busardo F, Carlier J Curr Neuropharmacol. 2023; 21(11):2323-2342.

PMID: 36946485 PMC: 10556379. DOI: 10.2174/1570159X21666230322143401.

References

Kirkland A, Fadus M, Gruber S, Gray K, Wilens T, Squeglia L . A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry Res. 2021; 308:114347. PMC: 8799523. DOI: 10.1016/j.psychres.2021.114347. View

WATSON D, Clark L, Tellegen A . Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988; 54(6):1063-70. DOI: 10.1037//0022-3514.54.6.1063. View

Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F . Cannabidiol (CBD) use in psychiatric disorders: A systematic review. Neurotoxicology. 2019; 74:282-298. DOI: 10.1016/j.neuro.2019.08.002. View

Hindocha C, Freeman T, Grabski M, Stroud J, Crudgington H, Davies A . Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction. 2018; . PMC: 6099309. DOI: 10.1111/add.14243. View

Fullerton C, Kim M, Thomas C, Lyman D, Montejano L, Dougherty R . Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2013; 65(2):146-57. DOI: 10.1176/appi.ps.201300235. View

Fatseas M, Denis C, Massida Z, Verger M, Franques-Reneric P, Auriacombe M . Cue-induced reactivity, cortisol response and substance use outcome in treated heroin dependent individuals. Biol Psychiatry. 2011; 70(8):720-727. DOI: 10.1016/j.biopsych.2011.05.015. View

McHugh R, Park S, Weiss R . Cue-induced craving in dependence upon prescription opioids and heroin. Am J Addict. 2014; 23(5):453-8. PMC: 4163930. DOI: 10.1111/j.1521-0391.2014.12129.x. View

Carroll K, Weiss R . The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review. Am J Psychiatry. 2016; 174(8):738-747. PMC: 5474206. DOI: 10.1176/appi.ajp.2016.16070792. View

Sordo L, Barrio G, Bravo M, Indave B, Degenhardt L, Wiessing L . Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017; 357:j1550. PMC: 5421454. DOI: 10.1136/bmj.j1550. View

10.

Morgan C, Freeman T, Schafer G, Curran H . Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010; 35(9):1879-85. PMC: 2906701. DOI: 10.1038/npp.2010.58. View

11.

Freeman T, Hindocha C, Baio G, Shaban N, Thomas E, Astbury D . Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020; 7(10):865-874. PMC: 7116091. DOI: 10.1016/S2215-0366(20)30290-X. View

12.

Kroenke K, Spitzer R, Williams J . The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9):606-13. PMC: 1495268. DOI: 10.1046/j.1525-1497.2001.016009606.x. View

13.

Hurd Y, Yoon M, Manini A, Hernandez S, Olmedo R, Ostman M . Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics. 2015; 12(4):807-15. PMC: 4604178. DOI: 10.1007/s13311-015-0373-7. View

14.

Spitzer R, Kroenke K, Williams J, Lowe B . A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006; 166(10):1092-7. DOI: 10.1001/archinte.166.10.1092. View

15.

Batalla A, Bos J, Postma A, Bossong M . The Impact of Cannabidiol on Human Brain Function: A Systematic Review. Front Pharmacol. 2021; 11:618184. PMC: 7858248. DOI: 10.3389/fphar.2020.618184. View

16.

Suzuki J, Weiss R . Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence?. J Addict Med. 2020; 15(2):91-92. PMC: 7986228. DOI: 10.1097/ADM.0000000000000711. View

17.

Preston K, Kowalczyk W, Phillips K, Jobes M, Vahabzadeh M, Lin J . Exacerbated Craving in the Presence of Stress and Drug Cues in Drug-Dependent Patients. Neuropsychopharmacology. 2017; 43(4):859-867. PMC: 5809798. DOI: 10.1038/npp.2017.275. View

18.

McHugh R, Fitzmaurice G, Carroll K, Griffin M, Hill K, Wasan A . Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients. Drug Alcohol Depend. 2014; 145:121-6. PMC: 4254575. DOI: 10.1016/j.drugalcdep.2014.10.002. View

19.

Boyaji S, Merkow J, Elman R, Kaye A, Yong R, Urman R . The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence. Curr Pain Headache Rep. 2020; 24(2):4. DOI: 10.1007/s11916-020-0835-4. View

20.

Wesson D, Ling W . The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003; 35(2):253-9. DOI: 10.1080/02791072.2003.10400007. View